Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study

Mise à jour : Il y a 4 ans
Référence : NCT00674362

Femme et Homme

Extrait

To assess the clinical efficacy and safety of certolizumab pegol as add-on therapy with stable-dose disease-modifying antirheumatic drugs (DMARDs) for achieving clinical remission in patients with moderate to low disease activity rheumatoid arthritis


Critère d'inclusion

  • Rheumatoid Arthritis


Liens